RT @NatureNews: Genome editing: 7 facts about a revolutionary technology https://t.co/vRb9gaK8gA #CRISPR pic.twitter.com/ZreHXPISge
— Dale Yuzuki (@DaleYuzuki) December 1, 2015
Reproducibility Project scaled back https://t.co/5bTR99U8ff but problem of reproducibility of published science continues. New ideas needed.
— David Maizenberg (@biologypartners) December 3, 2015
Read the STAMPEDE trial will help you understand metastatic prostate cancer & increase your IQ for the New Year https://t.co/u6gdKkWzGD
— daviesbj (@daviesbj) December 22, 2015
Think this is the 4th recent study suggesting classical model of hematopoiesis is incorrect https://t.co/npB84L8CX9 pic.twitter.com/gJEPqZ7m8E
— Skeptical PhD (@SkepticalPhD) December 28, 2015
Summary in @nejm of @ASCO framework on value-based cancer care. Worthwhile for every hematologist/oncologist. https://t.co/v1pGd7ir4C
— Krishna Komanduri (@drkomanduri) December 31, 2015
Never seen 3 simultaneous papers before...In-vivo correction of #DMD via CRISPR $SRPT $BMRN
https://t.co/OfjhO5gvjp pic.twitter.com/hguHOqGQwn
— Skeptical PhD (@SkepticalPhD) December 31, 2015
Our @JAMA_current article on how @US_FDA can help stop the monopolization of #generic drugs https://t.co/SGFGxctJsT
— Joshua Sharfstein (@drJoshS) January 4, 2016
How bad is science's #credibilitycrisis? @PLOSBiology launches section on research about research: https://t.co/qiYZyB4aXD This sd be good
— sharon begley (@sxbegle) January 4, 2016
and for good measure, Cell also published a review by Jennifer Doudna https://t.co/mQfLphhMju
— Nicolas Robine (@notSoJunkDNA) January 14, 2016
An (obviously entirely unbiased) history of CRISPR discovery, by Eric Lander (or the Broad’s lawyers and PR firm?) https://t.co/tKkulpindV
— Nicolas Robine (@notSoJunkDNA) January 14, 2016
This is the NEJM piece that has open science tweeps totally ripped https://t.co/N7S9FQjc8D #dataparasites
— Ryan McBride (@rymcbr) January 22, 2016
Rescheduling hydrocodone saw 14 million fewer Rxs, 750 million fewer tablets at one year https://t.co/kaujvCXlx2 pic.twitter.com/CXe5vEZAAh
— David Juurlink (@DavidJuurlink) January 25, 2016
Wow, $KITE $JUNO won't like this - https://t.co/NTsDLauWBq What's the point of autologous tx for $400k when allogeneic getting same results?
— Vikram Khanna (@VikramKhanna_) January 26, 2016